Pulmonx (LUNG) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
Annual Meeting scheduled for June 4, 2026, at 8:00 AM PT, accessible virtually for all shareholders.
Shareholders are encouraged to review proxy materials online or request copies before May 21, 2026.
Voting matters and shareholder proposals
Election of three directors: Thomas W. Burns, Georgia Garinois-Melenikiotou, and Dana G. Mead, Jr.
Ratification of BDO USA, LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Non-binding advisory vote to approve executive compensation (say-on-pay).
Proxy holders may vote on other business arising at the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of all proposals, including director nominees and auditor ratification.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Pulmonx
- Q2 2026 revenue was $22.8M, net loss improved, and gross margin hit 78%.LUNG
Q2 20264 Aug 2026 - 2026 guidance targets $90–92M revenue, improved margins, and lower cash burn after a transitional 2025.LUNG
Q4 20259 Jul 2026 - Q1 revenue rose 20% to $22.5M, with strong international growth and reaffirmed guidance.LUNG
Q1 20258 Jul 2026 - Q2 revenue hit $20.8M, up 21% year-over-year, with improved margins and narrowed net loss.LUNG
Q2 20248 Jul 2026 - Strong growth, clinical progress, and workflow innovation set the stage for global expansion.LUNG
2024 Wells Fargo Healthcare Conference8 Jul 2026 - 2024 revenue rose 22% to $83.8M, with 2025 guidance for 15–18% growth and stable margins.LUNG
Q4 20248 Jul 2026 - All proposals passed, including director elections and auditor ratification, with no shareholder questions.LUNG
AGM 202610 Jun 2026 - Innovative valve therapy for emphysema drives global growth and expands market reach.LUNG
Bank of America Global Healthcare Conference 202613 May 2026 - Q1 2026 revenue fell 9% year-over-year, but gross margin rose to 78% and net loss narrowed.LUNG
Q1 20264 May 2026